Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 234

1.

Allelic expression imbalance of JAK2 V617F mutation in BCR-ABL negative myeloproliferative neoplasms.

Kim HR, Choi HJ, Kim YK, Kim HJ, Shin JH, Suh SP, Ryang DW, Shin MG.

PLoS One. 2013;8(1):e52518. doi: 10.1371/journal.pone.0052518. Epub 2013 Jan 22.

2.

The C allele of JAK2 rs4495487 is an additional candidate locus that contributes to myeloproliferative neoplasm predisposition in the Japanese population.

Ohyashiki JH, Yoneta M, Hisatomi H, Iwabuchi T, Umezu T, Ohyashiki K.

BMC Med Genet. 2012 Jan 17;13:6. doi: 10.1186/1471-2350-13-6.

3.

[JAK2 V617F and exon 12 genetic variations in Korean patients with BCR/ABL1-negative myeloproliferative neoplasms].

Kim JT, Cho YG, Choi SI, Lee YJ, Kim HR, Jang SJ, Moon DS, Park YJ, Park G.

Korean J Lab Med. 2010 Dec;30(6):567-74. doi: 10.3343/kjlm.2010.30.6.567. Korean.

4.

Rapid identification of heterozygous or homozygous JAK2(V617F) mutations in myeloproliferative neoplasms using melting curve analysis.

Ho CL, Wu YY, Hung HM, Chang PY, Kao WY, Chen YC, Chao TY.

J Formos Med Assoc. 2012 Jan;111(1):34-40. doi: 10.1016/j.jfma.2012.01.003. Epub 2012 Feb 1.

5.

JAK2-V617F mutation in Moroccan patients with myeloproliferative disorders: contribution, diagnosis and therapeutic prospects.

Benmoussa A, Dehbi H, Fehri S, Quessar A, Nadifi S.

Pathol Biol (Paris). 2011 Aug;59(4):e89-92. doi: 10.1016/j.patbio.2009.06.005. Epub 2009 Nov 24.

PMID:
19939582
6.

[Clinical significance of the quantification of JAK2V617F allele burden in classical Ph-negative myeloproliferative neoplasms].

Kerguelén Fuentes AE, Hernández-Maraver D, Lombardia L, Canales Albendea MA, Rodriguez de la Rúa A.

Med Clin (Barc). 2012 Oct 13;139(9):373-8. doi: 10.1016/j.medcli.2012.03.032. Epub 2012 Jun 27. Spanish.

PMID:
22743278
7.

Differences in the JAK2 and MPL mutation status in the cell lineages of the bcr/abl-negative chronic myeloproliferative neoplasm subtypes.

Toyama K, Karasawa M, Yokohama A, Mitsui T, Uchiumi H, Saitoh T, Handa H, Murakami H, Nojima Y, Tsukamoto N.

Intern Med. 2011;50(21):2557-61. Epub 2011 Nov 1.

8.

JAK2-v617F mutation is associated with clinical and laboratory features of myeloproliferative neoplasms.

Duletić AN, Dekanić A, Hadzisejdić I, Kusen I, Matusan-Ilijas K, Grohovac D, Grahovac B, Jonjić N.

Coll Antropol. 2012 Sep;36(3):859-65.

PMID:
23213945
9.

Concomitant BCR-ABL1 translocation and JAK2(V617F) mutation in three patients with myeloproliferative neoplasms.

Hummel JM, Kletecka MC, Sanks JK, Chiselite MD, Roulston D, Smith LB, Czuchlewski DR, Elenitoba-Johnson KS, Lim MS.

Diagn Mol Pathol. 2012 Sep;21(3):176-83. doi: 10.1097/PDM.0b013e318246975e.

PMID:
22847163
10.

JAK2 V617F mutation prevalence in myeloproliferative neoplasms in Pernambuco, Brazil.

da Silva RR, Domingues Hatzlhofer BL, Machado CG, Lima AS, de Albuquerque DM, dos Santos MN, Fertrin KY, Costa FF, Araújo Ada S, Bezerra MA.

Genet Test Mol Biomarkers. 2012 Jul;16(7):802-5. doi: 10.1089/gtmb.2011.0272. Epub 2012 Feb 3.

PMID:
22304488
11.

The G allele of the JAK2 rs10974944 SNP, part of JAK2 46/1 haplotype, is strongly associated with JAK2 V617F-positive myeloproliferative neoplasms.

Trifa AP, Cucuianu A, Petrov L, Urian L, Militaru MS, Dima D, Pop IV, Popp RA.

Ann Hematol. 2010 Oct;89(10):979-83. doi: 10.1007/s00277-010-0960-y. Epub 2010 Apr 27.

PMID:
20422415
12.

The Prevalence of JAK2, MPL, and CALR Mutations in Chinese Patients With BCR-ABL1-Negative Myeloproliferative Neoplasms.

Lin Y, Liu E, Sun Q, Ma J, Li Q, Cao Z, Wang J, Jia Y, Zhang H, Song Z, Ai X, Shi L, Feng X, Li C, Wang J, Ru K.

Am J Clin Pathol. 2015 Jul;144(1):165-71. doi: 10.1309/AJCPALP51XDIXDDV.

PMID:
26071474
13.

[Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].

Rajnai H, Bödör C, Reiniger L, Timár B, Csernus B, Szepesi A, Csomor J, Matolcsy A.

Orv Hetil. 2006 Nov 12;147(45):2175-9. Hungarian.

PMID:
17402211
14.

Genetic association between germline JAK2 polymorphisms and myeloproliferative neoplasms in Hong Kong Chinese population: a case-control study.

Koh SP, Yip SP, Lee KK, Chan CC, Lau SM, Kho CS, Lau CK, Lin SY, Lau YM, Wong LG, Au KL, Wong KF, Chu RW, Yu PH, Chow EY, Leung KF, Tsoi WC, Yung BY.

BMC Genet. 2014 Dec 20;15:147. doi: 10.1186/s12863-014-0147-y.

15.

JAK2 V617F patients with essential thrombocythemia present with clinical features of polycythemia vera.

Zhang S, Qiu H, Fischer BS, Li W, Duan L, Sun X, Xu W, Li J.

Leuk Lymphoma. 2008 Apr;49(4):696-9. doi: 10.1080/10428190701885537.

PMID:
18398736
16.

Role of JAK2 V617F mutation and aberrant expression of microRNA-143 in myeloproliferative neoplasms.

Benati M, Montagnana M, Danese E, De Matteis G, Veneri D, Paviati E, Guidi GC.

Clin Chem Lab Med. 2015 Jun;53(7):1005-11. doi: 10.1515/cclm-2014-0858.

PMID:
25527813
17.

What is the role of JAK2(V617F) mutation in leukemic transformation of myeloproliferative neoplasms?

Lopes da Silva R, Ribeiro P, Lourenço A, Santos SC, Santos M, Costa I, de Sousa AB.

Lab Hematol. 2011 Mar;17(1):12-6. doi: 10.1532/LH96.10018.

PMID:
21421540
18.

Analysis of JAK2V617F mutation in Jordanian patients with myeloproliferative neoplasms.

Jaradat SA, Khasawneh R, Kamal N, Matalka I, Al-Bishtawi M, Al-Sweedan S, Ayesh MH.

Hematol Oncol Stem Cell Ther. 2015 Dec;8(4):160-6. doi: 10.1016/j.hemonc.2015.07.004. Epub 2015 Aug 1.

19.

Association between thromboembolic events and the JAK2 V617F mutation in myeloproliferative neoplasms.

Takata Y, Seki R, Kanajii T, Nohara M, Koteda S, Kawaguchi K, Nomura K, Nakamura T, Morishige S, Oku E, Osaki K, Hashiguchi E, Mouri F, Yoshimoto K, Nagafuji K, Okamura T.

Kurume Med J. 2014;60(3-4):89-97. Epub 2014 May 26.

20.

[The investigation of JAK2 V617F point mutation in myeloproliferative disorders by allele-specific polymerase chain reaction in combination with sequence analysis].

Zhang SJ, Li WD, Song JH, Xu W, Qiu HX, Li JY.

Zhonghua Yi Xue Za Zhi. 2007 Aug 14;87(30):2109-12. Chinese.

PMID:
17988529

Supplemental Content

Support Center